ADHD

Getting a good night’s rest is vital for neurodiverse children – pediatric sleep experts explain why

Retrieved on: 
Friday, April 19, 2024

If you’re a parent with kids at home, it often leaves you and your children on edge.

Key Points: 
  • If you’re a parent with kids at home, it often leaves you and your children on edge.
  • Children with neurodiverse conditions, such as autism and attention-deficit/hyperactivity disorder, or ADHD, are even more susceptible to the effects of poor sleep, given their emotional reactivity and impulsivity..
  • Struggles with sleep have been linked to increased aggression, irritability, inattention and hyperactivity in children with autism spectrum disorder.

The science behind sleep difficulties

  • There are multiple reasons why neurodiverse children don’t sleep well, including medical conditions, biological causes and behavioral and environmental factors.
  • Medical conditions, such as obstructive sleep apnea or epilepsy, can affect a child’s sleep.
  • Medications that are used to treat medical conditions, such as antidepressants for mood disorders or stimulants for ADHD, can further disrupt sleep.

Treating sleep problems


All of these factors can be addressed and treated. A thorough evaluation by the child’s health care provider may reveal a medical cause, or medication, that is interfering with sleep. Behavioral approaches can make a big difference in improving sleep. These might include:
Changes to daytime habits, including getting lots of morning light and physical activity.
Shifts in evening habits, such as removing all screens (TV, computers, phones, etc.) and establishing calming bedtime routines.
Modifications to how a parent interacts with their child for those families who would like a child to fall asleep and stay asleep independently.

  • It’s important to note that not all families want their children to sleep on their own.
  • Because there are so many factors that can cause disrupted sleep, addressing sleep problems cannot be a one-size-fits-all approach and should be done in partnership with parents.
  • Our team has developed a family-centered approach to address sleep problems in neurodiverse children.

The ups and downs of melatonin

  • While behavioral approaches are recommended as a first-line treatment, melatonin can be helpful in jump-starting a behavioral routine.
  • Overdoses can result from children eating a bunch of gummies, or parents not understanding how much melatonin is safe to give.
  • To help parents sift through all the resources and articles on melatonin on the internet and social media, one of us created a video and wrote several blogs on melatonin safety.
  • These include topics like whether children can become dependent on melatonin supplements over time, whether taking melatonin will delay puberty, whether children might experience side effects from taking melatonin and more.

Promoting healthier sleep


Here are some general tips for helping your child sleep better, regardless of whether they are neurodiverse:
Choose a consistent bedtime and wake time. This consistency will help children’s own natural melatonin kick in.
Make sure bedtime isn’t too early. For example, an 8 p.m. bedtime is too early for most 10-year-olds. Neurodiverse children may struggle to sleep and will become more anxious, which makes going to sleep even harder.
Help your child get natural sunlight in the morning. Morning sunlight sets our brain’s internal clock so that we can fall asleep more easily at bedtime.
Ensure your child is getting physical activity during the day.
Minimize naps longer than one hour, or after 4 p.m. for school-age children. Naps can interfere with going to sleep at night.
Avoid caffeine, including many types of soda, tea and chocolate.
Turn off all screens and smartphones at least 30 minutes before bedtime.
In the evening leading up to bedtime, turn down all lights in the house. Consider using red night lights, if possible. Set any devices to night mode in the evening to limit exposure to blue light.
Create wind-down time in place of screens. Have your child identify an activity they enjoy that is calming and soothing, such as reading a book, coloring or listening to music. If a bath is stimulating, move it to earlier in the evening, such as after dinner.
Help your child learn to fall asleep without needing you or their devices to be there with them. That way, they will settle down on their own at bedtime. And when they wake up throughout the night, since we all wake up in the night, they will be able to go right back to sleep without becoming fully awake.
For more tips, see Autism Speaks for free downloads of brochures and visual aids.

  • She also receives funding from the American Academy of Sleep Medicine.
  • She has received funding from the American Academy of Sleep Medicine and Autism Speaks for research on sleep in children with ASD.

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, April 1, 2024

KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update. Highlights include capital raised from multiple sources and the addition of three independent board members.

Key Points: 
  • “Our lead asset CTx-1301 continues to impress clinical investigators and key opinion leaders as we share our Phase 3 results.
  • These tailwinds put Cingulate in a position to obtain non-dilutive capital and expand our pipeline of assets.
  • Looking ahead, Cingulate has several financial instruments in place to raise additional capital while fighting to preserve shareholder’s equity.
  • “Overall, I am very pleased with the progress made by our team in 2023 and into 2024.

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

Retrieved on: 
Wednesday, March 27, 2024

"We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.

Key Points: 
  • "We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.
  • Established in 2016, The Neuropsychiatry & TMS Group, led by Dr. Ahmed, has been dedicated to delivering exceptional mental health services.
  • With the support of Beacon, The Neuropsychiatry & TMS Group anticipates continued growth opportunities, including expanding its TMS services and recruiting additional physicians.
  • “I am pleased to announce our recent expansion into Florida, a natural progression for Beacon,” says Beacon Behavioral Partners CEO Sean Wendell.

Cingulate to Participate in Benzinga All Live Access Event

Retrieved on: 
Tuesday, March 19, 2024

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday March 22, 2024, at 12 p.m.

Key Points: 
  • KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday March 22, 2024, at 12 p.m.
  • ET.
  • Dr. Schaffer will also provide a company overview and recap recent Cingulate clinical and business updates.
  • The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulate’s website at cingulate.com/investors .

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Retrieved on: 
Tuesday, March 19, 2024

FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine .

Key Points: 
  • FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine .
  • Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary.
  • CEO Insights Asia writes that Dr. Patil, "a unique amalgamation of scholarly acumen and practical insight fuels a forward-thinking approach, steering companies toward sustained success and pioneering innovation ( CEO Insight Asia 19) ".
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

WaveDancer and Firefly Neuroscience, an AI-Driven Brain Health Company, Each Receive Respective Stockholder Approvals for Merger

Retrieved on: 
Monday, March 18, 2024

FAIRFAX, Va., March 18, 2024 (GLOBE NEWSWIRE) -- WaveDancer, Inc. (“WaveDancer”) (Nasdaq: WAVD) and Firefly Neuroscience, Inc. (“Firefly”) an AI-driven brain health company, each received the requisite stockholder approvals required to consummate the merger between both companies.

Key Points: 
  • FAIRFAX, Va., March 18, 2024 (GLOBE NEWSWIRE) -- WaveDancer, Inc. (“WaveDancer”) (Nasdaq: WAVD) and Firefly Neuroscience, Inc. (“Firefly”) an AI-driven brain health company, each received the requisite stockholder approvals required to consummate the merger between both companies.
  • The Firefly approval was obtained through a written consent by the holders of a majority of the outstanding voting shares of Firefly.
  • "The WaveDancer favorable shareholder vote is an important step in consummating the merger and reinventing WaveDancer as an AI-enabled neurological health platform,” said Jamie Benoit, Chairman and CEO of WaveDancer.
  • WaveDancer has filed with the SEC a Registration Statement, which includes a proxy statement/prospectus of WaveDancer that sets forth relevant information pertaining to the merger.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

Corgan and University of Arkansas Win AIA Upjohn Research Initiative Grant to Study ADHD and Workplace Design

Retrieved on: 
Tuesday, April 2, 2024

Global architecture and design firm Corgan , in partnership with the University of Arkansas, has received a research grant from the American Institute of Architects (AIA) Upjohn Research Initiative to study workplace design for neurodivergent people, specifically for those with ADHD.

Key Points: 
  • Global architecture and design firm Corgan , in partnership with the University of Arkansas, has received a research grant from the American Institute of Architects (AIA) Upjohn Research Initiative to study workplace design for neurodivergent people, specifically for those with ADHD.
  • Corgan—Hugo, the firm’s research and innovation group, will partner with the university on research with the goal of identifying successful inclusive design strategies.
  • Corgan will make the research insights accessible to designers all over the world via a workspace design guidebook in the spring 2025.
  • The AIA Upjohn Research Initiative supports research projects that enhance the value of design, funding up to six research grants annually.

J.P. Morgan Wealth Management and Entrepreneur Daniella Pierson Will Host Event to Help Women Build Financial Freedom

Retrieved on: 
Wednesday, March 13, 2024

J.P. Morgan Wealth Management and Daniella Pierson, founder and CEO of The Newsette Media Group, are teaming up to help empower people to build their financial freedom.

Key Points: 
  • J.P. Morgan Wealth Management and Daniella Pierson, founder and CEO of The Newsette Media Group, are teaming up to help empower people to build their financial freedom.
  • The event, co-hosted by Daniella and Kristin Lemkau, CEO of J.P. Morgan Wealth Management, will feature powerful programming meant to inspire and give attendees the tools they need to help build their financial future and freedom.
  • With the BE A BREADWINNER brand, Daniella Pierson wants to provide informative, inspiring, and actionable content to anyone interested in taking control of their future to achieve financial freedom and independence.
  • In 2022, she was named one of Barron’s “10 People to Watch in Wealth Management” and inducted into Forbes’ CMO Hall of Fame.

Student-Athletes with Self-Reported Autism Spectrum Disorder are More Likely to Score Low on Common Concussion Test, Raising the Need for Autism-Specific Comparison Data

Retrieved on: 
Thursday, March 28, 2024

PHILADELPHIA, March 28, 2024 /PRNewswire/ -- Schools and colleges across the country rely on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) evaluations to assess and manage student-athlete concussions on the sidelines. However, this FDA-cleared tool is not recommended for student-athletes with neurodevelopmental disorders, who often score significantly lower than neurotypical individuals. New research published Feb. 13 in the Archives of Clinical Neuropsychology demonstrates the need for alternative or modified concussion assessment norms and the need for baseline testing for autistic athletes.

Key Points: 
  • However, this FDA-cleared tool is not recommended for student-athletes with neurodevelopmental disorders, who often score significantly lower than neurotypical individuals.
  • "The [neuropsychology] field needs to expand assessment and interpretation practices and procedures for people with ASD and related developmental conditions."
  • Individuals with attention deficit hyperactivity disorder (ADHD), learning disorder (LD) and ASD are not included in normative reference data.
  • This means when autistic athletes are assessed for a concussion, their data is compared to age- and gender-similar neurotypical individuals.